Natural killer cells trigger differentiation of monocytes into dendritic cells. by Zhang, A, Colmenero, P, Purath, U, Teixeira de Matos, C, Hueber, W, Klareskog, L, Tarner, I, Engleman, E, Söderström, K

A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. by Monach, P, Hueber, W, Kessler, B, Tomooka, B, BenBarak, M, Simmons, B, Wright, J, Thornhill, T, Monestier, M, Ploegh, H, Robinson, W, Mathis, D, Benoist, C

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS by Emery, P, Baeten, D, Sieper, J, Braun, J, van der Heijde, D, McInnes, I, Van Laar, J, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Paramarta, I, Bertolino, A, Wright, A, Hueber, W

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS by Van Laar, J, Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. by Hueber, W, Sands, B, Lewitzky, S, Vandemeulebroecke, M, Reinisch, W, Higgins, P, Wehkamp, J, Feagan, BG, Yao, MD, Karczewski, M, Karczewski, J, Pezous, N, Bek, S, Bruin, G, Mellgard, B, Berger, C, Londei, M, Bertolino, A, Tougas, G, Travis, S

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial by Hueber, W, Sands, B, Lewitzky, S, Vandemeulebroecke, M, Reinisch, W, Higgins, P, Wehkamp, J, Feagan, BG, Yao, MD, Karczewski, M, Karczewski, J, Pezous, N, Bek, S, Bruin, G, Mellgard, B, Berger, C, Londei, M, Bertolino, A, Tougas, G, Travis, S

LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOS... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. by Baeten, D, Baraliakos, X, Braun, J, Sieper, J, Emery, P, van der Heijde, D, McInnes, I, van Laar, J, Landewé, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Wei, J, Brachat, A, Bek, S, Laurent, D, Li, Y, Wang, Y, Bertolino, A, Gsteiger, S, Wright, A, Hueber, W